NCT04616222

Brief Summary

Celsior® is an organ preservation solution used for the harvesting and the preservation of solid organs. Its use as a crystalloid cardioplegia solution has been established recently. Its main advantage is the long duration of myocardial protection. Compared to the other cardioplegia solutions, it allows a reduced amount of solution administered during the surgery and fewer interruptions during the intervention for the administration of supplemental doses of cardioplegia for long and complex operations. The objective of this register is to compare the safety and the efficacy of Celsior® to the old cardioplegia solution Saint-Thomas used as cardioplegia solution in surgery of the transposition of great vessels, the arterial switch operation.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 23, 2020

Completed
1 month until next milestone

Study Start

First participant enrolled

September 1, 2020

Completed
2 months until next milestone

First Posted

Study publicly available on registry

November 4, 2020

Completed
27 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
Last Updated

November 6, 2020

Status Verified

July 1, 2020

Enrollment Period

3 months

First QC Date

July 23, 2020

Last Update Submit

November 5, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Death at 30 days after surgery

    Death at 30 days after surgery

    30 days

Secondary Outcomes (4)

  • Post-operative troponin levels

    48 hours

  • Cardiac rhythm assessment

    24 hours

  • Variation of pre- and post-operative creatinine levels

    24 hours

  • Intensive care unit length of stay

    30 days

Study Arms (2)

CELSIOR® group

Patient who received Celsior® during their transposition of the great vessels surgery

Drug: CELSIOR® group

Saint-Thomas group

Patient who received Saint-Thomas during their transposition of the great vessels surgery

Drug: Saint-Thomas group

Interventions

Patient who received Celsior® during their transposition of the great vessels surgery according to the routine care.

CELSIOR® group

Patient who received Saint-Thomas during their transposition of the great vessels surgery according to the routine care.

Saint-Thomas group

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Paediatric patients with an arterial switch operation for transposition of the great vessels

You may qualify if:

  • Patient of neonatal age at the time of the intervention
  • Patients with a transposition of the great vessels with intact septum and with the arterial switch operation performed as a corrective procedure
  • CELSIOR® used as cardioplegia solution between 2012 and 2019
  • Saint-Thomas used as cardioplegia solution (control group) between 2005 and 2011

You may not qualify if:

  • Major cardiovascular malformations needing correction during the surgery for the transposition of great vessels including : interventricular communication, coarctation of the aorta, interruption of the aortic arch
  • Significant anomalies of coronary arteries origin or paths including : intramural course, single coronary ostium
  • Opposition to participate in this retrospective research

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

: Hôpital Louis Pradel - Service de Chirurgie Cardiaque C

Bron, 69477, France

RECRUITING

Related Publications (1)

  • Bulescu NC, Mitchell J, Metton O, El Jonhy N, Amaz C, Perouse de Montclos T, Lilot M, Mewton N, Henaine R. Celsior(R) vs. St Thomas(R) cardioplegia: analysis of myocardial protection and clinical safety in neonates. Front Pediatr. 2024 Jul 8;12:1430832. doi: 10.3389/fped.2024.1430832. eCollection 2024.

MeSH Terms

Conditions

Transposition of Great Vessels

Condition Hierarchy (Ancestors)

Heart Defects, CongenitalCardiovascular AbnormalitiesCardiovascular DiseasesHeart DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 23, 2020

First Posted

November 4, 2020

Study Start

September 1, 2020

Primary Completion

December 1, 2020

Study Completion

December 1, 2020

Last Updated

November 6, 2020

Record last verified: 2020-07

Locations